Precigen is excited to announce that the FDA has accepted and granted priority review to the BLA for our lead asset, PRGN-2012, an investigational AdenoVerse therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP). The FDA has set the PDUFA target action date of August 27, 2025. View press release: https://bit.ly/4bhTbTV
Precigen
生物技术研究
Germantown，Maryland 5,956 位关注者
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies.
关于我们
Precigen: Advancing Medicine with Precision? Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
- 网站
-
https://www.precigen.com
Precigen的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Germantown，Maryland
- 类型
- 上市公司
- 领域
- Gene Therapy和Cell Therapy
地点
-
主要
获取路线
20358 Seneca Meadows Pkwy
US，Maryland，Germantown，20876
Precigen员工
动态
-
On this #RareDiseaseDay, we'd like to give a special shout-out to our advocacy partner - RECURRENT RESPIRATORY PAPILLOMATOSIS FOUNDATION - who we have worked so closely?with over the last few years?as we progressed our?clinical development program to address the unmet needs of RRP patients. We are forever?grateful for your insights, input to help guide our work, for the awareness you raise about this rare and devastating disease, and for the tremendous support you provide and community you've built. Learn more about RRPF and the great work they are doing at www.rrpf.org.
-
-
We are thrilled to announce that Precigen is a finalist for the Maryland Tech Council Icon Awards as Emerging Life Sciences Company of the Year and our President and CEO, Helen Sabzevari, PhD, is a finalist for Life Sciences CEO of the Year. Thank you to the MTC for recognizing the work of our company and our leadership. Learn more about MTC's Icon awards:?https://bit.ly/4gZVQTc View MTC's Icon awards press release: https://bit.ly/4ibwLFY
-
-
Helen Sabzevari, PhD, President and CEO of Precigen, joins #CellAndGenePodcast host, Erin Harris of Cell & Gene,?to discuss how our AdenoVerse platform has the potential to transform medicine. Plus, she recaps Precigen’s recent BLA submission for PRGN-2012 and pivotal trial results. Listen now!?https://bit.ly/40ENsCJ
-
-
Check out the commentary titled "A high-impact study and landmark achievement in the treatment of recurrent respiratory papillomatosis" from Craig S. Derkay, MD, on the latest publication in The Lancet Respiratory Medicine regarding?Precigen's PRGN-2012 pivotal study in RRP (requires subscription):?https://bit.ly/40GkNhA
-
Just published online! Pivotal Phase 1/2 clinical trial results for Precigen's investigational PRGN-2012 in recurrent respiratory papillomatosis have been published in The Lancet Respiratory Medicine. View publication (requires subscription): https://bit.ly/4g6RMAb #ClinicalTrails
-
-
Thank you to all who attended Precigen's company presentation at the 43rd Annual JP Morgan Healthcare Conference moderated by Brian Cheng of JP Morgan and featuring Precigen President and CEO Helen Sabzevari and Chief Commercial Officer Phil Tennant where we laid out our plans for our commercial vision for PRGN-2012. #ICYMI, please check out the replay. https://bit.ly/3WlSP8s #JPM25 #JPM2025
-
-
Welcome to the team Gaetano Bonifacio!
I'm excited to share that I've officially started a new role as Vice President, Head of Medical Affairs at Precigen. I am very grateful for the opportunity to join this world class team. Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. With the recently announced completion of the rolling submission for a BLA?to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis, the year ahead of us looks promising and full of opportunities. Thank you so much for such a warm welcome and for making me feel part of the Precigen family. Special Thanks to Helen Sabzevari Phil Tennant Rutul Shah Amy Lankford Dough Brough Harry Thomasian Don Lehr Joe Merkert Rob Russell for this incredible opportunity.
此处无法显示此内容
在领英 APP 中访问此内容等
-
Precigen's President and CEO, Helen Sabzevari, PhD, to present at the 43rd Annual JP Morgan Healthcare Conference in San Francisco. View details: https://bit.ly/4fqC2sq #JPM2025 #JPM25
-